'Sitting on a Potential Blockbuster'
Market 'Pain' Heed to Zalicus: Phase II Results Coming Soon
By Randy Osborne
Staff Writer
Staff Writer
Zalicus Inc.'s shares gained ground the day after second-quarter earnings rolled out, as investors reawakened to the potential of Z160, the firm's Phase II oral, N-type calcium channel blocker for chronic pain.